Patents by Inventor Frederick Wong
Frederick Wong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11918697Abstract: This disclosure includes a description of a sanitizing system for sanitizing a mobile electronic device comprising: a housing; a sanitizer contained within the housing configured to emit radiation with a sanitizing effect; and an entry system with a default closed position, the entry system being configured to permit a mobile electronic device to pass through the entry system and then automatically return to the default closed position, the entry system comprising a first outer enclosure and a second inner obstruction; wherein the entry system blocks radiation emitted within the sanitizing system to a level acceptable for consumer use, or wherein the second inner obstruction provides more radiation attenuation than the first outer enclosure, and/or wherein the combination of the first outer enclosure and the second inner obstruction provides more radiation attenuation than the first outer enclosure by itself. Disclosed are internal reflectors to help distribute sanitizing radiation generally evenly.Type: GrantFiled: August 2, 2021Date of Patent: March 5, 2024Assignee: simplehuman, LLCInventors: Frank Yang, Ryan Wong, Cory Bowman, Frederick Bushroe, William Patrick Conley, Nasser Pirshafiey
-
Patent number: 6498165Abstract: Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of protein tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogensis, atheroscelerosis, graft rejection, rheumatoid arthritis and psoriasis.Type: GrantFiled: June 26, 2000Date of Patent: December 24, 2002Assignee: Merck & Co., Inc.Inventors: Helen M. Armstrong, Richard Beresis, Joung L. Goulet, Mark A. Holmes, Xingfang Hong, Sander G. Mills, William H. Parsons, Peter J. Sinclair, Mark G. Steiner, Frederick Wong, Dennis M. Zaller
-
Patent number: 5693648Abstract: Substituted compounds of the FK-506 Type. These compounds are useful for the same or essentially the same purposes as FK-506 and are applied in the same or a similar manner. These compounds are immunosuppressants and useful for the treatment of autoimmune diseases, infectious diseases and/or the prevention of rejection of foreign organ transplants. Still other uses are described in the disclosure.Type: GrantFiled: March 27, 1996Date of Patent: December 2, 1997Assignee: Merck & Co., Inc.Inventors: Mark Goulet, Helen M. Organ, William H. Parsons, Peter J. Sinclair, Frederick Wong, Matthew J. Wyvratt
-
Patent number: 5565560Abstract: O-Aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides of the general structural Formula I: ##STR1## have been prepared from suitable precursors by alkylation and/or arylation at C-3" and/or C-4" of the cyclohexyl ring. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases and/or the prevention of rejection of foreign organ transplants and/or related afflictions, diseases and illnesses.Type: GrantFiled: October 4, 1993Date of Patent: October 15, 1996Assignee: Merck & Co., Inc.Inventors: Mark Goulet, Helen M. Organ, William H. Parsons, Peter J. Sinclair, Frederick Wong, Matthew J. Wyvratt
-
Patent number: 5532248Abstract: O-Aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides of the general structural Formula I: ##STR1## have been prepared from suitable precursors by alkylation and/or arylation at C-3" and/or C-4" of the cyclohexyl ring. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases and/or the prevention of rejection of foreign organ transplants and/or related afflictions, diseases and illnesses.Type: GrantFiled: May 12, 1995Date of Patent: July 2, 1996Assignee: Merck Co., Inc.Inventors: Mark Goulet, William H. Parsons, Helen M. Organ, Peter J. Sinclair, Frederick Wong, Matthew J. Wyvratt
-
Patent number: 5349061Abstract: O-Heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroaryl-macrolides of the general structural Formula I: ##STR1## have been prepared from suitable precursors by alkylation and/or arylation at C-3" and/or C-4" of the cyclohexyl ring. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases, the prevention of rejection of foreign organ transplants and/or related afflictions, diseases and illnesses.Type: GrantFiled: October 12, 1993Date of Patent: September 20, 1994Assignee: Merck & Co., Inc.Inventors: Peter J. Sinclair, Joung Goulet, Frederick Wong, Mark Goulet, William H. Parsons, Matthew J. Wyvratt
-
Patent number: 5344925Abstract: Imidazolidyl macrolides of the general structural Formula I: ##STR1## have been prepared from suitable precursors by alkylation and/or arylation at C-3" and/or C-4" of the cyclohexyl ring. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases the prevention of rejection of foreign organ transplants and/or related afflictions, diseases and illnesses.Type: GrantFiled: September 20, 1993Date of Patent: September 6, 1994Assignee: Merck & Co., Inc.Inventors: Mark Goulet, Peter J. Sinclair, Frederick Wong, Matthew J. Wyvratt
-
Patent number: 5310901Abstract: O-Heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylrapamycin derivatives of the general structural Formula I: ##STR1## have been prepared from suitable precursors by alkylation and/or arylation at C-42 and/or C-31. These compounds are useful in a mammalian host for the treatment of autoimmune diseases and diseases of inflammation, infectious diseases, the prevention of rejection of foreign organ transplants and the treatment of solid tumors.Type: GrantFiled: March 5, 1993Date of Patent: May 10, 1994Assignee: Merck & Co., Inc.Inventors: William H. Parsons, Peter J. Sinclair, Frederick Wong, Matthew J. Wyvratt
-
Patent number: 5258389Abstract: O-Aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives of the general structural Formula I: ##STR1## have been prepared from suitable precursors by alkylation and/or arylation at C-42 and/or C-31. These compounds are useful in a mammalian host for the treatment of autoimmune diseases and diseases of inflammation, infectious diseases, the prevention of rejection of foreign organ transplants and the treatment of solid tumors.Type: GrantFiled: November 9, 1992Date of Patent: November 2, 1993Assignee: Merck & Co., Inc.Inventors: Mark Goulet, William H. Parsons, Peter J. Sinclair, Frederick Wong, Matthew J. Wyvratt
-
Patent number: 5252732Abstract: O-Heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides of the general structural Formula I: ##STR1## have been prepared from suitable precursors by alkylation and/or arylation at C-3" and/or C-4" of the cyclohexyl ring. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases, the prevention of rejection of foreign organ transplants and/or related afflictions, diseases and illnesses.Type: GrantFiled: August 5, 1992Date of Patent: October 12, 1993Assignee: Merck & Co., Inc.Inventors: Peter J. Sinclair, Joung Goulet, Frederick Wong, Mark Goulet, William H. Parsons, Matthew J. Wyvratt
-
Patent number: 5250678Abstract: O-Aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides of the general structural Formula I: ##STR1## have been prepared from suitable precursors by alkylation and/or arylation at C-3" and/or C-4" of the cyclohexyl ring. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases and/or the prevention of rejection of foreign organ transplants. In addition, these macrolide immunosuppressants are useful in the topical treatment of inflammatory and hyperproliferative skin diseases and cutaneous manifestations of immunologically-mediated illnesses.Type: GrantFiled: May 1, 1992Date of Patent: October 5, 1993Assignee: Merck & Co., Inc.Inventors: Mark Goulet, Frederick Wong, Peter J. Sinclair, Matthew J. Wyvratt
-
Patent number: 5247076Abstract: Imidazolidyl macrolides of the general structural Formula I: ##STR1## have been prepared from suitable precursors by alkylation and/or arylation at C-3" and/or C-4" of the cyclohexyl ring. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases the prevention of rejection of foreign organ transplants and/or related afflictions, diseases and illnesses.Type: GrantFiled: August 4, 1992Date of Patent: September 21, 1993Assignee: Merck & Co., Inc.Inventors: Mark Goulet, Peter J. Sinclair, Frederick Wong, Matthew J. Wyvratt
-
Patent number: 4866205Abstract: New optically active intermediates and processes thereto are provided for use in synthesizing therapeutically active prostaglandins of the formula: ##STR1## wherein R.sup.1 is hydrogen or lower alkyl; from a compound of the formula: ##STR2## wherein R.sup.1 is as above and R.sup.2 is hydrogen or a carboxy blocking group convertible to an acid by hydrolysis.Type: GrantFiled: July 11, 1988Date of Patent: September 12, 1989Assignees: Hoffman-La Roche Inc., Hoffman-La Roche Inc.Inventors: David L. Coffen, George W. Holland, W. Harry Mandeville, Perry Rosen, Frederick Wong
-
Patent number: 4707555Abstract: New optically active intermediates and processes thereto are provided for use in synthesizing therapeutically active prostaglandins of the formula: ##STR1## wherein R.sup.1 is hydrogen or lower alkyl; from a compound of the formula: ##STR2## wherein R.sup.1 is as above and R.sup.2 is hydrogen or a carboxy blocking group convertible to an acid by hydrolysis.Type: GrantFiled: July 12, 1985Date of Patent: November 17, 1987Assignee: Hoffmann-La Roche Inc.Inventors: David L. Coffen, George W. Holland, W. Harry Mandeville, Perry Rosen, Frederick Wong
-
Patent number: 4558140Abstract: New optically active intermediates and processes thereto are provided for use in synthesizing therapeutically active prostaglandins of the formula: ##STR1## wherein R.sup.1 is hydrogen or lower alkyl; from a compound of the formula: ##STR2## wherein R.sup.1 is as above and R.sup.2 is hydrogen or a carboxy blocking group convertible to an acid by hydrolysis.Type: GrantFiled: March 6, 1984Date of Patent: December 10, 1985Assignee: Hoffmann-La Roche Inc.Inventors: David L. Coffen, George W. Holland, Perry Rosen, Frederick Wong